UTRN and Duchenne muscular dystrophy: Clinical trials with SMT C1100, optimization of further compounds in this chemical series and the discovery of other chemical entities with similar utrophin‐modulating effects may eventually lead to an effective disease‐modifying therapy for DMD regardless of the dystrophin mutation.